Citation Information :
Mani R K, Gupte V, Gogtay J. A questionnaire-based survey of physician perceptions of the prevalence of antimicrobial resistance and their antibiotic prescribing patterns. Indian J Crit Care Med 2018; 22 (7):491-497.
Background: Antibiotic resistance is a serious problem being faced by physicians worldwide. This article was designed to study physician perceptions of antibiotic resistance and their prescribing patterns.
Materials and Methods: A structured questionnaire was developed for reporting the prevalence of antibiotic resistance as perceived by physicians and recording their antibiotic preferences in specific contexts. A total of 539 intensivists across India participated in the study.
Results: The prevalence of multidrug-resistant (MDR) Gram-negative pathogens was reported to be on the rise in Intensive Care Units. The prevalence rate of carbapenem-resistant Enterobacteriaceae was reported to be between 20% and 40% by 33% of the participants. Piperacillin-tazobactam was the preferred beta-lactam/beta-lactamase inhibitor antibiotic by the majority of intensivists (47%) in the treatment of infections caused by extended-spectrum beta-lactamase producers. Meropenem was recommended to be used at a higher dose (2 g t.i.d.) by 41% of intensivists for Pseudomonas/Acinetobacter infections with high minimum inhibitory concentration values for meropenem. De-escalation data revealed that 43% of intensivists “always” would like to de-escalate from carbapenems, based on the antibiotic susceptibility data. Minocycline was recommended by 33% for the treatment of ventilator-associated pneumonia (VAP) and by 21% for bloodstream infections caused by MDR Acinetobacter. Up to 83% of intensivists preferred the use of nebulized colistin for the management of VAP/hospital-acquired pneumonia.
Conclusion: This study reveals that the prevalence of MDR Gram-negative pathogens is perceived to be on the rise. Prescription patterns indicate high levels of variability. Hence, antibiotic stewardship is essential to standardize antibiotic prescriptions not only for efficacy but also to reduce the burden of multiple drug resistance.
Palmer AC, Kishony R. Understanding, predicting and manipulating the genotypic evolution of antibiotic resistance. Nat Rev Genet 2013;14:243-8.
Vincent JL, Bassetti M, François B, Karam G, Chastre J, Torres A, et al. Advances in antibiotic therapy in the critically ill. Crit Care 2016;20:133.
Tennant I, Nicholson A, Gordon-Strachan GM, Thoms C, Chin V, Didier MA, et al. Asurvey of physicians' knowledge and attitudes regarding antimicrobial resistance and antibiotic prescribing practices at the University Hospital of the West Indies. West Indian Med J 2010;59:165-70.
Kumar SG, Adithan C, Harish BN, Sujatha S, Roy G, Malini A, et al. Antimicrobial resistance in India: A review. J Nat Sci Biol Med 2013;4:286-91.
Manerikar V, Manerikar S. Cronbach's alpha. aWEshkar 2015; XIX: 117-19.
Odonkor ST, Addo KK. Bacteria resistance to antibiotics: Recent trends and challenges. Int J Biol Med Res 2011;2:1204-10.
Chakraborty P, Mukherjee S. A study on the prevalence and microbiological profile of nosocomial infections in the ICU of a tertiary care hospital in Eastern India. Int J Curr Microbiol Appl Sci 2016;5:920-5.
Amreliwala S, Durgad S, Poojary A. Carbapenem-sparing options for the treatment of ESBL- and AmpC-producing Enterobacteriaceae in hemodynamically stable patients – An in vitro study. Int J Curr Microbiol Appl Sci 2015;4:513-21.
Sharma S, Gupta S, Arora A. Cefepime Tazobactam: A new β lactam/β lactamase inhibitor combination against ESBL-producing Gram-negative bacilli. Int J Pharm Biomed Sci 2012;3:35-8.
Luyt CE, Aubry A, Lu Q, Micaelo M, Bréchot N, Brossier F, et al. Imipenem, meropenem, or doripenem to treat patients with Pseudomonas aeruginosa ventilator-associated pneumonia. Antimicrob Agents Chemother 2014;58:1372-80.
Fernández Viladrich P. The role of meropenem in bacterial meningitis. Enferm Infecc Microbiol Clin 1997;15 Suppl 1:57-61.
Daoud Z, Mansour N, Masri K. Synergistic combination of carbapenems and colistin against P. aeruginosa and A. baumannii. Open J Med Microbiol 2013;3:253-8.
Lew KY, Ng TM, Tan M, Tan SH, Lew EL, Ling LM, et al. Safety and clinical outcomes of carbapenem de-escalation as part of an antimicrobial stewardship programme in an ESBL-endemic setting. J Antimicrob Chemother 2015;70:1219-25.
Sastry S, Doi Y. Fosfomycin: Resurgence of an old companion. J Infect Chemother 2016;22:273-80.
Slover CM, Rodvold KA, Danziger LH. Tigecycline: A novel broad-spectrum antimicrobial. Ann Pharmacother 2007;41:965-72.
Ritchie DJ, Garavaglia-Wilson A. A review of intravenous minocycline for treatment of multidrug-resistant Acinetobacter infections. Clin Infect Dis 2014;59 Suppl 6:S374-80.
Dewan A, Shoukat M. Evaluation of risk of nephrotoxicity with high dose, extended-interval colistin administration. Indian J Crit Care Med 2014;18:427-30.
Kalil AC, Metersky ML, Klompas M, Muscedere J, Sweeney DA, Palmer LB, et al. Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the infectious diseases society of America and the American Thoracic Society. Clin Infect Dis 2016;63:e61-111.
Karaiskos I, Galani L, Baziaka F, Giamarellou H. Intraventricular and intrathecal colistin as the last therapeutic resort for the treatment of multidrug-resistant and extensively drug-resistant Acinetobacter baumannii ventriculitis and meningitis: A literature review. Int J Antimicrob Agents 2013;41:499-508.
Cai Y, Lee W, Kwa AL. Polymyxin B versus colistin: An update. Expert Rev Anti Infect Ther 2015;13:1481-97.